The clinical significance of an ILD diagnosis together with the relatively high incidence of ILD induced by some anti-HER2 therapies highlights the need for consensus in ILD monitoring and management guidelines in the context of anticancer treatment for metastatic disease. Here, ERBB2 is linked to interstitial lung disease.